CoChat

Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the french society of paediatric oncology

Open access
Gentet, J.-C., Brunat-Mentigny, M., Demaille, M.C., Pein, F., Avet-Loiseau, H., Berger, C., De Lumley, L., Pacquement, H., Schmitt, C., Sariban, E., Pillon, P., Bernard, J.L., Kalifa, C. · 1997 · European Journal of Cancer

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

The aim of this phase II study was to determine the efficacy of high-dose ifosfamide with moderate dose etoposide in childhood osteosarcoma. From January 1992 to January 1995, 27 children (15 male, 12 female) with relapsed or refractory evaluable osteosarcoma were included in a phase II study of two courses of ifosfamide 3g/m2/day and etoposide 75 mg/m2/day for 4 days. Median age was 14 years (7-19 years). All but one had received high-dose methotrexate and doxorubicin as first-line treatment. 22 patients had previously received ifosfamide. This regimen was given as first-line in 1 patient, second-line in 23 and third-line in 3. Evaluable disease was lung metastases in 21 patients, local relapse in 5 and adenopathy in 1. There were six complete responses, seven partial responses, three minor responses, six stable disease and five progressive disease (including one mixed response). Response rate was 48% (95% confidence interval, 29-67%). Duration of response was not available (10 responding patients had other treatments). Response rate was equivalent in the subgroup of 22 patients who had previously received ifosfamide (4 CR, 6 PR). Among 3 patients who received the phase II regimen as third-line chemotherapy, there was 1 PR. All but 4 patients had a well tolerated grade 4 neutropenia. Transient mild confusion or seizures were each observed once. 5 patients are alive 15-31 months after the beginning of chemotherapy. This combination of drugs at this dosage has tolerable toxicity, is efficient and deserves evaluation in phase III studies.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0959-8049(96)00439-x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 15 references

Research works printed but not linked: 2

  1. Pratt, 1987, Phase II trial of ifosfamide in children with malignant tumors, Cancer Treat Rep, 71, 131
  2. Miser, 1987, Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults, J Clin Oncol, 5, 1191, 10.1200/jco.1987.5.8.1191 · DOI · Paper page

Cited by

See all 86

Metadata

Authors
Gentet, J.-C., Brunat-Mentigny, M., Demaille, M. C., Pein, F., Avet-Loiseau, H., Berger, C., De Lumley, L., Pacquement, H., Schmitt, C., Sariban, E., Pillon, P., Bernard, J. L., & Kalifa, C.
Affiliations
  • Centre Léon Bérard (FR)
  • Centre Oscar Lambret (FR)
  • Institut Gustave Roussy (FR)
  • Centre Hospitalier Universitaire de Saint-Étienne (FR)
  • Institut Curie (FR)
  • Centre Hospitalier Régional et Universitaire de Nancy (FR)
  • Queen Fabiola Children's University Hospital (BE)
Corresponding author
Gentet, J.-C.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
1997-02
Volume
33
Issue
2
Pages
232-237
ISSN
0959-8049 (ISSN-L)
OpenAlex
W2018217408
Cited by
86
References
15
Citations by year
2026: 1 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 2 · 2020: 8 · 2019: 1 · 2018: 1 · 2017: 4 · 2016: 2 · 2015: 6 · 2014: 5 · 2013: 3 · 2012: 3
FWCI
1.11
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • European Journal of Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Keywords
ifosfamide, etoposide, high-dose chemotherapy, second-line chemotherapy, lung metastasis, neutropenia, chemotherapy toxicity, treatment response rate
MeSH terms
Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Etoposide, Female, Humans, Ifosfamide, Male, Osteosarcoma, Survival Rate, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the french society of paediatric oncology. https://app.cochat.ai/papers/10.1016/s0959-8049(96)00439-x
The paper
Gentet, J.-C., Brunat-Mentigny, M., Demaille, M. C., Pein, F., Avet-Loiseau, H., Berger, C., De Lumley, L., Pacquement, H., Schmitt, C., Sariban, E., Pillon, P., Bernard, J. L., & Kalifa, C. (1997). Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the french society of paediatric oncology. European Journal of Cancer. https://doi.org/10.1016/s0959-8049(96)00439-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.